Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sanofi (SAN.PA)
Paris, FR
Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 10 | 0 |
| Hold | 11 | +1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%-1.5% Q1'26: +6.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+45.8% ★ Q1'26: -2.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+15.9% Q1'26: +60.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+15.4% Q1'26: +19.4% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+6.5% Q1'26: +7.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-2.5% ★ Q1'26: -2.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×3.23× Q1'26: 1.84× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 9 EPS Ana. |
Dec 2027 8 Rev. Ana. 12 EPS Ana. |
Dec 2028 7 Rev. Ana. 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
35.06B
est: 33.78B (+3.8%)
|
35.96B
est: 35.65B (+0.8%)
|
31.29B
est: 33.70B (-7.2%)
|
32.00B
est: 34.06B (-6.0%)
|
34.86B
est: 37.25B (-6.4%)
|
34.70B
est: 36.00B (-3.6%)
|
36.22B
est: 35.78B (+1.2%)
|
35.68B
est: 34.86B (+2.3%)
|
37.63B
est: 37.23B (+1.1%)
|
37.37B
est: 36.92B (+1.2%)
|
39.18B
est: 38.76B (+1.1%)
|
40.30B
est: 44.58B (-9.6%)
|
41.11B
est: 47.08B (-12.7%)
|
44.29B
est: 43.67B (+1.4%)
|
43.63B
est: 45.45B (-4.0%)
|
48.55B
47.71B – 50.29B
+6.8% YoY
|
51.52B
50.07B – 53.77B
+6.1% YoY
|
54.02B
53.08B – 54.96B
+4.9% YoY
|
56.17B
54.89B – 58.41B
+4.0% YoY
|
58.60B
57.26B – 60.94B
+4.3% YoY
|
| EBITDA |
10.64B
est: 12.43B (-14.4%)
|
12.50B
est: 12.02B (+4.0%)
|
9.62B
est: 10.14B (-5.1%)
|
9.87B
est: 9.84B (+0.3%)
|
10.23B
est: 9.18B (+11.5%)
|
10.36B
est: 8.85B (+17.1%)
|
10.28B
est: 9.45B (+8.8%)
|
9.36B
est: 13.24B (-29.3%)
|
10.11B
est: 9.22B (+9.6%)
|
10.47B
est: 10.32B (+1.4%)
|
11.25B
est: 10.77B (+4.4%)
|
13.09B
est: 11.22B (+16.7%)
|
11.08B
est: 12.23B (-9.5%)
|
11.66B
est: 12.41B (-6.0%)
|
6.74B
est: 11.81B (-42.9%)
|
12.62B
12.40B – 13.07B
+6.8% YoY
|
13.39B
13.01B – 13.97B
+6.1% YoY
|
14.04B
13.79B – 14.28B
+4.9% YoY
|
14.60B
14.26B – 15.18B
+4.0% YoY
|
15.23B
14.88B – 15.84B
+4.3% YoY
|
| EBIT |
6.00B
est: 6.43B (-6.7%)
|
7.97B
est: 6.05B (+31.8%)
|
6.11B
est: 6.04B (+1.2%)
|
6.75B
est: 5.16B (+30.8%)
|
6.97B
est: 6.79B (+2.6%)
|
7.52B
est: 5.45B (+37.9%)
|
7.27B
est: 6.46B (+12.5%)
|
6.02B
est: 5.65B (+6.7%)
|
6.80B
est: 4.90B (+38.7%)
|
7.58B
est: 3.17B (+139.3%)
|
8.57B
est: 3.30B (+159.2%)
|
10.38B
est: 3.44B (+201.6%)
|
8.12B
est: 9.68B (-16.1%)
|
8.87B
est: 9.26B (-4.2%)
|
6.74B
est: 9.35B (-27.9%)
|
9.99B
9.81B – 10.34B
+6.8% YoY
|
10.60B
10.30B – 11.06B
+6.1% YoY
|
11.11B
10.92B – 11.31B
+4.9% YoY
|
11.55B
11.29B – 12.01B
+4.0% YoY
|
12.05B
11.78B – 12.53B
+4.3% YoY
|
| Net Income |
5.69B
est: 5.90B (-3.5%)
|
4.89B
est: 6.01B (-18.7%)
|
3.72B
est: 4.73B (-21.5%)
|
4.39B
est: 3.76B (+16.9%)
|
4.29B
est: 4.87B (-11.9%)
|
4.71B
est: 4.19B (+12.3%)
|
8.42B
est: 5.11B (+64.7%)
|
4.31B
est: 8.19B (-47.4%)
|
2.75B
est: 4.52B (-39.0%)
|
12.29B
est: 2.84B (+332.3%)
|
6.22B
est: 2.97B (+109.7%)
|
8.37B
est: 3.09B (+170.9%)
|
5.40B
est: 4.22B (+28.1%)
|
5.56B
est: 9.02B (-38.4%)
|
7.81B
est: 9.47B (-17.5%)
|
10.43B
10.11B – 10.75B
+10.2% YoY
|
10.79B
9.69B – 11.89B
+3.5% YoY
|
10.52B
10.00B – 13.90B
-2.5% YoY
|
13.43B
13.03B – 14.13B
+27.6% YoY
|
14.55B
14.12B – 15.31B
+8.4% YoY
|
| SGA |
8.54B
est: 8.17B (+4.5%)
|
9.13B
est: 9.01B (+1.3%)
|
8.11B
est: 8.52B (-4.9%)
|
8.57B
est: 8.63B (-0.8%)
|
9.50B
est: 10.03B (-5.3%)
|
9.59B
est: 9.13B (+5.1%)
|
10.16B
est: 9.32B (+9.0%)
|
9.93B
est: 9.80B (+1.4%)
|
9.97B
est: 10.25B (-2.8%)
|
9.45B
est: 9.90B (-4.6%)
|
9.60B
est: 10.33B (-7.1%)
|
8.79B
est: 10.76B (-18.3%)
|
9.00B
est: 10.45B (-13.8%)
|
9.25B
est: 9.99B (-7.4%)
|
9.54B
est: 10.09B (-5.4%)
|
10.77B
10.59B – 11.16B
+6.8% YoY
|
11.43B
11.11B – 11.93B
+6.1% YoY
|
11.99B
11.78B – 12.20B
+4.9% YoY
|
12.46B
12.18B – 12.96B
+4.0% YoY
|
13.00B
12.71B – 13.52B
+4.3% YoY
|
| EPS |
4.31
est: 6.70 (-35.7%)
|
3.76
est: 6.25 (-39.8%)
|
2.81
est: 5.09 (-44.7%)
|
3.34
est: 5.23 (-36.1%)
|
3.28
est: 5.55 (-40.9%)
|
3.66
est: 5.56 (-34.1%)
|
6.71
est: 5.60 (+19.8%)
|
3.45
est: 5.43 (-36.5%)
|
2.24
est: 5.88 (-61.9%)
|
9.82
est: 5.77 (+70.2%)
|
4.97
est: 6.46 (-23.0%)
|
6.69
est: 8.23 (-18.7%)
|
4.31
est: 3.37 (+27.9%)
|
4.39
est: 7.31 (-40.0%)
|
6.40
est: 7.76 (-17.5%)
|
8.47
8.28 – 8.81
+9.2% YoY
|
9.01
7.94 – 9.74
+6.3% YoY
|
9.86
8.19 – 11.39
+9.4% YoY
|
11.01
10.68 – 11.58
+11.7% YoY
|
11.93
11.57 – 12.54
+8.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-07-10 | Sanofi | Director | P-Purchase | A | Common Stock | 2,470 | 306.77 | 757.7K | 21,603,211 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul Hudson | CEO & Director | 4M | male |
| Felix Lauscher | Head of IR North America & Asia | — | male |
| François-Xavier Roger | Executive VP & CFO | — | male |
| Madeleine Roach | Executive VP & Head of Business Operations | — | female |
| Natalie Bickford | Executive VP & Chief People Officer | — | female |
| Olivier Charmeil | Executive Vice President of General Medicines | — | male |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | — | male |
| Roy Papatheodorou | Executive VP & General Counsel | — | male |
| Fabrizio Gaudi | Head of Austrian, German & Swiss Operations | — | — |
| Thomas Kudsk Larsen | Head of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SAN.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
